C/EBPα Is Required for Long-Term Self-Renewal and Lineage Priming of Hematopoietic Stem Cells and for the Maintenance of Epigenetic Configurations in Multipotent Progenitors by Hasemann, Marie S et al.
u n i ve r s i t y  o f  co pe n h ag e n  
Københavns Universitet
C/EBP Is Required for Long-Term Self-Renewal and Lineage Priming of Hematopoietic
Stem Cells and for the Maintenance of Epigenetic Configurations in Multipotent
Progenitors
Hasemann, Marie S; Lauridsen, Felicia K B; Waage, Johannes; Jakobsen, Janus S; Frank,
Anne-Katrine; Schuster, Mikkel B; Rapin, Nicolas Philippe Jean-Pierre; Bagger, Frederik O;
Hoppe, Philipp S; Schroeder, Timm; Porse, Bo T
Published in:
P L o S Genetics (Online)
DOI:
10.1371/journal.pgen.1004079
Publication date:
2014
Document version
Publisher's PDF, also known as Version of record
Citation for published version (APA):
Hasemann, M. S., Lauridsen, F. K. B., Waage, J., Jakobsen, J. S., Frank, A-K., Schuster, M. B., ... Porse, B. T.
(2014). C/EBP Is Required for Long-Term Self-Renewal and Lineage Priming of Hematopoietic Stem Cells and
for the Maintenance of Epigenetic Configurations in Multipotent Progenitors. P L o S Genetics (Online), 10(1), 1-
10. [e1004079]. https://doi.org/10.1371/journal.pgen.1004079
Download date: 03. Feb. 2020
C/EBPa Is Required for Long-Term Self-Renewal and
Lineage Priming of Hematopoietic Stem Cells and for the
Maintenance of Epigenetic Configurations in Multipotent
Progenitors
Marie S. Hasemann1,2,3, Felicia K. B. Lauridsen1,2,3, Johannes Waage1,2,3,4, Janus S. Jakobsen1,2,3, Anne-
Katrine Frank1,2,3, Mikkel B. Schuster1,2,3, Nicolas Rapin1,2,3,4, Frederik O. Bagger1,2,3,4, Philipp S. Hoppe5,
Timm Schroeder5, Bo T. Porse1,2,3,4*
1 The Finsen Laboratory, Rigshospitalet, Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark, 2 Biotech Research and Innovation Center (BRIC),
University of Copenhagen, Copenhagen, Denmark, 3Danish Stem Cell Centre (DanStem) Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark,
4 The Bioinformatic Centre, Department of Biology, Faculty of Natural Sciences, University of Copenhagen, Copenhagen, Denmark, 5Department of Biosystems Science
and Engineering, ETH Zurich, Basel, Switzerland
Abstract
Transcription factors are key regulators of hematopoietic stem cells (HSCs) and act through their ability to bind DNA and
impact on gene transcription. Their functions are interpreted in the complex landscape of chromatin, but current
knowledge on how this is achieved is very limited. C/EBPa is an important transcriptional regulator of hematopoiesis, but its
potential functions in HSCs have remained elusive. Here we report that C/EBPa serves to protect adult HSCs from apoptosis
and to maintain their quiescent state. Consequently, deletion of Cebpa is associated with loss of self-renewal and HSC
exhaustion. By combining gene expression analysis with genome-wide assessment of C/EBPa binding and epigenetic
configurations, we show that C/EBPa acts to modulate the epigenetic states of genes belonging to molecular pathways
important for HSC function. Moreover, our data suggest that C/EBPa acts as a priming factor at the HSC level where it
actively promotes myeloid differentiation and counteracts lymphoid lineage choice. Taken together, our results show that
C/EBPa is a key regulator of HSC biology, which influences the epigenetic landscape of HSCs in order to balance different
cell fate options.
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Introduction
Hematopoietic stem cells (HSCs) are responsible for the
maintenance of a constant production of blood cells throughout
life. To achieve this, HSCs have to tightly regulate their different
fate options including self-renewal, proliferation, differentiation
and apoptosis, as alterations in any of these may lead to HSC
exhaustion, expansion or leukemia [1]. HSC fate options are
controlled by a number of different pathways and are influenced
both by the microenvironment and by the actions of cell-
autonomous regulators such as transcription factors (TFs) and
chromatin-interacting proteins [2].
Given their impact on gene expression, the influence of TFs on
HSC properties has been the focus of several studies. Indeed, factors
such as C-MYB, ERG, and PU.1 are all essential for preserving
HSC self-renewal and their deletion have dramatic impact on
hematopoietic maintenance both during fetal and adult life
[3,4,5,6]. Other factors, as exemplified by SOX17, are required
exclusively for the maintenance of fetal HSCs, whereas GFI-1 and
ETV6 only appear to play a role in an adult setting [7,8,9].
TF function is interpreted in a chromatin context and,
accordingly, chromatin readers and writers have been shown to
be important for HSC function and maintenance. Examples
include the PRC1 component BMI-1 [10,11], the maintenance
DNA methyltransferase DNMT1 [12,13] as well as the H3K4
methyltransferase MLL1 [14]. Despite the importance of both TFs
and chromatin context for HSC function, our knowledge on how
TF binding is interpreted within an epigenetic landscape, and how
they may influence epigenetic configurations remains limited.
Importantly, given their inherent developmental plasticity, stem
cells have been reported to exhibit unique epigenetic signatures of
which the so-called bivalent configuration is the best character-
ized. Work in ES cells has shown that bivalently marked genes are
lowly expressed, enriched in genes involved in development/
differentiation, and display active (H3K4me3) as well as repressive
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(H3K27me3) histone marks [15,16]. As stem cells progress along
the path of differentiation the bivalent configuration is resolved
into an active or repressed state with a concomitant upregulation
or downregulation, respectively, of the expression of previously
marked genes [15,16]. To what extent the bivalent signature is
influenced by loss of TFs in HSCs has not been characterized.
C/EBPa is an important myeloid TF that functions not only by
binding to regulatory DNA elements and directing transcription,
but also through its ability to constrain proliferation by inhibiting
the transcriptional activity of E2F-complexes [17,18,19,20]. In the
hematopoietic system loss of C/EBPa leads to a differentiation
block upstream of the Granulocytic Monocytic Progenitor (GMP)
accompanied by an accumulation of earlier stem and myeloid
progenitor populations [17,21].
In acute myeloid leukemia (AML), CEBPA is found mutated in
approximately 10% of cases, and studies in mouse have shown that
the tumor-suppressive functions of C/EBPa can be ascribed to its
ability to balance the proliferation and differentiation of hemato-
poietic stem and progenitor cells (HSPCs) populations [18,22].
Indeed, HSCs from mice harboring tumor-prone variants of C/
EBPa displayed altered cell cycle kinetics, but how this impacts on
HSC function was difficult to assess due to the leukemic
transformation in these animals. Furthermore, complete loss of
C/EBPa has been reported to endow fetal HSC-enriched
populations with a minor competitive advantage in a transplan-
tation setting [21] and C/EBPa has recently been shown to
control the fetal-to-adult switch of HSCs [23]. However, at present
we lack knowledge on the long-term self-renewal properties of C/
EBPa in normal adult HSCs as well as insights into how it
potentially may influence transcription and the epigenetic
configuration of these cells.
In the present work we have used mouse genetics to
characterize the role of C/EBPa in adult HSCs. We found that
loss of Cebpa leads to HSC exhaustion, identifying C/EBPa as a
crucial regulator of HSC self-renewal. To molecularly assess the
function of C/EBPa in HSCs, we combined gene expression
analysis with genome-wide profiling of key epigenetic marks and
C/EBPa binding using Chromatin ImmunoPrecipitation coupled
to sequencing (ChIP-seq). Our findings demonstrate that C/EBPa
modulates key pathways associated with HSC function and
differentiation, in part by affecting the epigenetic states of genes
associated with some of these.
Results
Loss of C/EBPa Affects the Numbers of
Immunophenotypic HSPCs
To investigate the functional importance of C/EBPa in the
HSPC compartment, we generated Cebpafl/fl and Cebpafl/fl;Mx1Cre
mice (hereafter termed Cebpafl/fl and CebpaD/D, respectively) and
injected them with pIpC. Mice were analyzed 18–21 days later at
which time point the Cebpa allele was completely recombined in
CebpaD/D mice (Figure S1A). Of note, bone marrows (BM) of
CebpaD/D mice had an approximately 30% reduction in cellularity
compared to Cebpafl/fl littermates due to the loss of neutrophil
granulocytes (Figure S1B, C).
In line with its requirement for myeloid differentiation [21]
publically available gene expression profiles (http://servers.binf.
ku.dk/hemaexplorer/) [24] revealed a distinct expression pattern
in which Cebpa is lowly expressed in the stem cell compartment
and becomes transiently upregulated during commitment to the
granulocytic monocytic lineage (Figure 1A). Flow cytometry-based
analyses of the myelo-erythroid progenitor compartment verified
the reported block in monocytic and granulocytic differentiation at
the preGM to GMP transition in CebpaD/D BMs and the
concomitant increase in erythroid and megakaryocytic progenitors
(Figure S1D, E) [17,21]. Moving further upstream in the
hematopoietic hierarchy, we found a prominent expansion of
the MPP compartment (LSK, CD1502, CD48+) whereas the
frequency of immunophenotypic HSCs (LSK, CD150+, CD482)
was unaltered. However, given the reduction in BM cellularity in
CebpaD/D mice this translates into a 50% reduction in the absolute
numbers of HSCs upon loss of C/EBPa (Figure 1B, C).
Loss of Cebpa Compromises HSC Activity and Leads to
Their Exhaustion
The reduction of absolute HSC numbers suggests an unchar-
acterized function of C/EBPa in HSC biology. To test this
functionally, we first transplanted BM from CebpaD/D and Cebpafl/fl
mice non-competitively into lethally irradiated recipient mice.
Whereas all mice receiving Cebpafl/fl BM cells survived, 4/16 of
those receiving CebpaD/D BM died within 16 weeks (Figure 1D). In
the remaining mice CebpaD/D donor cells contributed to the
peripheral blood to a similar extent as the Cebpafl/fl control at 8 and
16 weeks post-transplantation, but exhibited a lower level of
reconstitution at three weeks post-transplantation due to the
requirement of C/EBPa for the production of the early
reconstituting neutrophil granulocytes (Figure 1E). Importantly,
we find the recipients to be completely devoid of donor-derived
granulocytes at all time points (Figure 1F and data not shown)
showing that Cebpa is fully recombined in the transplanted cells
and that it is equally important for granulocytic differentiation in a
transplantation setting. Remarkably, the frequency of CebpaD/D
HSCs was reduced 20-fold in the recipient BMs 16-weeks post-
transplantation, whereas the effects on other HSPC subsets were
similar to those observed in non-transplanted animals (Figure 1G).
To assess this further, we serially transplanted BM from primary
recipients and found that only 3/17 of the secondary recipients
reconstituted with CebpaD/D BM survived 16 weeks post-trans-
plantation (Figure 1D).
Author Summary
Hematopoietic stem cells (HSCs) are required for the
lifelong generation of blood cells. To fulfill this require-
ment HSCs carefully balance cell fate decisions such as self-
renewal, differentiation, quiescence, proliferation and
death. These features are regulated in part by transcription
factors, which act by controlling the expression of genes
important for the functional properties of HSCs. C/EBPa is
a well-known inducer of myeloid differentiation. It is lowly
expressed in HSCs and its potential function in these cells
has been extensively debated. Here, we demonstrate that
Cebpa deletion impacts on HSC self-renewal, differentia-
tion, quiescence and survival. Through gene expression
and ChIP-seq analyses of stem and progenitor cell-
enriched cell populations, we further show that C/EBPa
binds to regulatory regions of genes that are induced
during granulocytic differentiation, suggesting that C/
EBPa acts to prime HSCs for differentiation along the
myeloid lineage. Finally, we demonstrate that C/EBPa loss
leads to epigenetic changes at genes central to HSC
biology, which implies that it may act to recruit chromatin
writers/erasers through mechanisms that remain to be
characterized. In conclusion, our work identifies C/EBPa as
a central hub for HSC function and highlights how a single
transcription factor may coordinate several HSC fate
options.
C/EBPa Is a Key Regulator of HSC Biology
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Competitive BM transplantation remains the gold standard for
the assessment of HSC function and we therefore transplanted
CD45.2 donor cells along with equal amounts of CD45.1
competitor cells. Despite the comparable HSC frequencies in
Cebpafl/fl and CebpaD/D donors, loss of Cebpa leads to a marked
reduction in donor contribution both to PB and to the HSC
compartment of the recipients at 18-week post-transplantation
(Figure 2A–C). Importantly, the competitive disadvantage of
CebpaD/D BM cells was further exacerbated upon re-transplanta-
tion of 1 million donor cells from primary recipients having equal
donor contributions, and resulted in their complete failure to
contribute to the HSPC compartment of secondary recipients
(Figure 2D). Next, we transplanted 20 highly purified (LSK,
CD150+, CD482, CD342) HSCs from Cebpafl/fl or CebpaD/D BM
together with 200.000 unfractionated competitor BM cells. In
accordance with our previous findings, CebpaD/D HSCs were
markedly impaired in hematopoietic reconstitution and their
contribution to the recipient HSC compartment was negligible
(Figure 2E–G). Furthermore, upon re-transplantation of the BM
from primary recipients, CebpaD/D donor cells were unable to
contribute to hematopoietic reconstitution in secondary recipients
(Figure 2H, I). Finally, by transplanting 3000 CFSE-labeled
HSCs (LSK, CD150+, CD482) and assessing their homing to
hematopoietic organs we could exclude any obvious role of C/
EBPa in HSC trafficking during hematopoietic reconstitution
(Figure 2J).
In conclusion, loss of Cebpa has profound effects on hematopoi-
etic reconstitution both in competitive and non-competitive
settings and collectively our functional analyses demonstrate an
essential role of C/EBPa in HSC self-renewal and in preventing
HSC exhaustion.
Cebpa Maintains HSC Quiescence and Protects Them
from Cell Death
Several reports have demonstrated that C/EBPa acts to restrict
proliferation and a number of distinct mechanisms have been
proposed (reviewed in [25]).
To test to what extent the anti-proliferative properties of C/
EBPa may explain the loss of self-renewal in Cebpa deficient HSCs,
we first analyzed the frequencies of replicating HSCs by in vivo
Figure 1. Loss of Cebpa affects HSC self-renewal. (A) Expression of Cebpa in different hematopoietic cell populations derived from the
HemaExplorer website (http://servers.binf.ku.dk/hemaexplorer/). (B) HSC analysis of Cebpafl/fl and CebpaD/D BM. (C) Quantification of the data in (B).
Cebpafl/fl (n = 7) and CebpaD/D (n = 7). Each panel shows one representative experiment out of three. (D) Survival curves of primary and secondary
recipients transplanted with Cebpafl/fl (primary: n = 12, secondary: n = 16) and CebpaD/D (primary: n = 16, secondary: n = 17) BM. (E) Contribution of
CD45.2 cells to the blood of primary recipients. Cebpafl/fl (n = 12) and CebpaD/D (n = 16). (F) Distribution of B, T and myeloid cells in the CD45.2+ blood
of primary recipients 16 week after transplantation. (G) BM analysis of primary recipients of Cebpafl/fl (n = 8) or CebpaD/D (n = 8) BM cells. Data are
represented as mean+SEM, ns designates not significant.
doi:10.1371/journal.pgen.1004079.g001
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BrdU incorporation. Surprisingly, we were unable to detect any
major differences in the amounts of BrdU+ HSCs within Cebpafl/fl
and CebpaD/D BMs (Figure 3A), suggesting that C/EBPa does not
affect DNA synthesis in HSCs per se. In contrast, we found that loss
of Cebpa lead to a marked exit from quiescence as evidenced by a
reduction of CebpaD/D HSCs in G0 (Ki67 negative) and a
compensatory increase of CebpaD/D HSCs in G1 (Figure 3B).
Finally, we also found that the exit from quiescence was
accompanied by a marked increase in CebpaD/D HSCs that
underwent cell death and that this effect was restricted to
immunophenotypic HSCs (Figure 3C).
We next tested the behavior of HSCs in vitro by first evaluating
proliferation and cell death of single-sorted HSCs. Consistent with
our in vivo analysis we found that loss of Cebpa resulted in both
fewer and smaller colonies accompanied by an increase in cell
death (Figure 3D, E). Secondly, we used single-cell tracking of
HSCs in vitro to monitor the cell cycle length during the first three
cell divisions [26]. Consistently, we detected no differences
between the average cell cycle lengths by comparing Cebpafl/fl
and CebpaD/D HSCs (Figure 3F). Thus both our in vivo and in vitro
analysis demonstrated that C/EBPa does not regulate HSC
proliferation per se but rather acts to maintain HSC quiescence and
to protect HSCs from cell death.
Collectively, our phenotypic profiling of Cebpa deficient HSCs
demonstrates that C/EBPa is a crucial regulator of the balance
between quiescence, proliferation and cell death in HSCs. Hence,
loss of C/EBPa leads to cell cycle entry, loss of HSC self-renewal
and cell death.
Figure 2. CebpaD/D HSCs are functionally compromised on a cell-to-cell basis. (A) Contribution of CD45.2 cells to the blood of primary
recipients. Cebpafl/fl (n = 13) and CebpaD/D (n = 13). (B) Distribution of B, T and myeloid cells in the CD45.2+ blood of primary recipients 16 week after
transplantation. (C) BM analysis of primary recipients transplanted with Cebpafl/fl (n = 11) or CebpaD/D (n = 12) BM in a 1:1 ratio with competitor BM. (D)
BM analysis of secondary recipients transplanted with BM from primary recipients receiving Cebpafl/fl (n = 8) or CebpaD/D (n = 7) BM in a 1:1 ratio with
competitor BM. (E) Contribution of CD45.2 cells to the blood of primary recipients transplanted with either Cebpafl/fl (n = 11) or CebpaD/D (n = 10)
HSCs. P value designates significance at 16 weeks. (F) Distribution of B, T and myeloid cells in the CD45.2+ blood of primary recipients transplanted
with either Cebpafl/fl or CebpaD/D HSCs 16 week after transplantation. (G) Contribution of CD45.2 cells to the BM and the frequency of HSCs within the
CD45.2 BM compartment in mice transplanted with either Cebpafl/fl (n = 6) or CebpaD/D (n = 9) HSCs (from E). (H) Contribution of CD45.2 cells to the
blood of secondary recipients transplanted with BM from primary recipients receiving either Cebpafl/fl (n = 6) or CebpaD/D (n = 6) HSCs. P value
designates significance at 16 weeks. (I) Contribution of CD45.2 cells to the BM of secondary transplanted mice. Cebpafl/fl (n = 6) and CebpaD/D (n = 7).
(J) Homing analysis of HSCs from CebpaD/D (n = 4) or Cebpafl/fl (n = 6) mice. Data are represented as mean+SEM, ns designates not significant.
doi:10.1371/journal.pgen.1004079.g002
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Loss of Cebpa Affects Gene Expression Programs
Associated with Stem Cell Functions and Differentiation
In order to get insights into the molecular mechanisms by which
C/EBPa controls HSC self-renewal, we performed microarray-
based gene expression analysis of Cebpafl/fl and CebpaD/D HSCs
(LSK, CD150+, CD482). In total, we found 110 and 261 genes to
be more than 1.5x down- and upregulated, respectively, in CebpaD/D
HSCs (P,0,05) (Figure 4A, B, Table S1, Figure S2A for verification
by qRT-PCR). Consistent with our phenotypic analysis, gene set
enrichment analysis (GSEA) demonstrated a marked negative
correlation between HSC signature genes and the CebpaD/D
genotype (Figure 4C). Among the gene sets correlating positively
with the CebpaD/D genotype we found numerous signatures involved
in quiescence/proliferation, which are likely to underlie the loss of
quiescence that we observed in CebpaD/D HSCs. Similarly, we also
found a positive correlation between the expression of apoptotic
signatures and the CebpaD/D genotype as well as an up-regulation of
gene sets involved in the DNA damage response pathway. The
relevance of the latter is supported by the 10-fold increase of
cH2AX (a marker of DNA damage) positive HSCs that we observe
in CebpaD/D BMs (Figure 4D). Thus the increased levels in cell death
and DNA damage observed upon loss of Cebpa are supported both
by phenotypic and gene expression analyses.
Finally, we noted that a number of gene signatures representing
distinct hematopoietic lineages were selectively deregulated in
CebpaD/D HSCs. Thus whereas the expression of granulocytic-
monocytic gene sets were downregulated, their lymphoid and
erythroid counterparts correlated positively with the CebpaD/D
genotype. These findings strongly suggest that C/EBPa primes
HSCs towards the granulocytic-monocytic lineage at the expense
of lymphoid and erythroid differentiation and therefore plays a key
role in specifying the lineage output from HSCs (Figure 4C).
Identification of C/EBPa Binding Sites in HSPCs
The gene expression analysis reported above identified numer-
ous genes that were de-regulated upon loss of C/EBPa, however
whether these are direct or indirect targets remained to be
determined. To assess this we performed ChIP-seq analysis for C/
EBPa binding in LSK cells, which contains a mixture of HSCs
and, predominantly, MPPs.
Despite its low expression, we identified 397 high-confidence C/
EBPa bound regions of which selected examples of ChIP-seq
coverage are shown in Figure 5A (replicate 1) and verified by qPCR
(Figure 5B, Table S2 for the full dataset and Figure S2B–D for data
concerning the second replicate). In general, the C/EBPa bound
regions were located closer to the transcription start site (TSS) of the
Figure 3. CebpaD/D HSCs do not have a proliferative advantage but are prone to cell death. (A) Incorporation of BrdU into Cebpafl/fl (n = 7)
or CebpaD/D (n = 7) HSCs. (B) Cell cycle analysis of Cebpafl/fl (n = 10) or CebpaD/D (n = 17) HSCs and MPPs using Ki67 and DAPI. (C) Cell death analysis of
Cebpafl/fl (n = 7) or CebpaD/D (n = 10) HSCs using Annexin V and DAPI (D) Colony forming ability of Cebpafl/fl (n = 9) or CebpaD/D (n = 9) HSCs in SFEM. (E)
Cebpafl/fl (n = 7) or CebpaD/D (n = 7) HSC colony size in SFEM. (F) Division rate of Cebpafl/fl (n = 5) and CebpaD/D (n = 5) HSC measured by long-term
single cell tracking. Data are represented as mean+SEM.
doi:10.1371/journal.pgen.1004079.g003
C/EBPa Is a Key Regulator of HSC Biology
PLOS Genetics | www.plosgenetics.org 5 January 2014 | Volume 10 | Issue 1 | e1004079
Figure 4. Gene expression profiling of CebpaD/D HSCs shows loss of stemness and biased lineage differentiation. (A) HSCs from
CebpaD/D and Cebpafl/fl mice were subjected to gene expression analysis. The table shows selected genes downregulated in CebpaD/D compared to
Cebpafl/fl HSCs. (B) Selected genes upregulated in CebpaD/D compared to Cebpafl/fl HSCs. (C) Gene set enrichment analysis of CebpaD/D HSCs compared
to Cebpafl/fl HSCs. (D) DNA damage as assessed by cH2AX staining of CebpaD/D (n = 9) and Cebpafl/fl (n = 8) HSCs. Data are represented as mean+SEM.
doi:10.1371/journal.pgen.1004079.g004
C/EBPa Is a Key Regulator of HSC Biology
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nearest gene than a random set of regions, and 39% were located at
proximal promoters within 5 kb from TSS (Figure 5C, Table S2).
Gratifyingly, motif search analysis in the immediate vicinity of the
C/EBPa peak summit (+/270 bps) identified C/EBP consensus
motifs to be markedly overrepresented, however we also identified
enrichment of RUNX, ETS and SP1 binding motifs (Figure 5D,
Table S3). Interestingly, we find that PU.1 (an ETS factor) and
EGR2 (reported to bind SP1 motifs [27,28]) target genes to be
downregulated and upregulated, respectively in CebpaD/D HSCs
(LSK, CD150+, CD482) (Figure 5E). This might suggest that C/
EBPa activate and repress the expression of selected PU.1 and
EGR2 target genes, respectively, in HSCs in order to restrict
lymphoid and promote myeloid differentiation, thereby providing
further support for its lineage priming function.
We next took advantage of the Genomic Regions Enrichment of
Annotations Tool (GREAT), which predicts functions of cis-
regulatory regions by associating proximal and distal genomic
regions with putative targets [29]. Interestingly, C/EBPa associ-
ated genes were enriched in a number of gene ontology (GO)
categories, the majority of which were involved in myeloid
differentiation (Figure 5F, Table S4). Surprisingly, the expression of
genes belonging to these GO categories was not prominently de-
regulated in CebpaD/D HSCs (Figure 5G). One explanation could
be that C/EBPa marks genes, which are to be expressed at latter
stages of myeloid differentiation. Indeed, we find that genes
belonging to the GO categories abnormal myeloid leukocyte morphology
and increased granulocyte numbers, which were enriched for C/EBPa-
associated genes, were upregulated during myeloid differentiation
(Figure 5H). Finally, when we compare the overlap between C/
EBPa bound regions in LSK cells to a similar dataset derived from
GMPs, we find all regions bound by C/EBPa in LSKs to be
occupied in GMPs as well. (Figure 5I, Table S5). Thus our data is
consistent with a lineage priming function for C/EBPa.
Finally, in order to identify direct C/EBPa target genes in
HSCs, we correlated changes in gene expression in CebpaD/D
HSCs with the nearest C/EBPa bound region identified by ChIP-
seq in LSK cells. In total 6/102 genes (6%) and 21/257 (8%) of the
down- and upregulated genes, respectively, contained a C/EBPa
bound region within 100 kb from the TSS (Table S6). Hence, the
vast majority of genes displaying altered expression in CebpaD/D
HSCs did not have a nearby C/EBPa binding site and are
therefore unlikely to be directly regulated by C/EBPa in HSCs.
The identified list of genes targeted by C/EBPa in HSCs/MPPs
includes C/EBPa target genes known from other cell types such as
Hmox1 and Itgal, but also new and interesting target genes such as
Hmbs, Ccnd2 and Emilin2. The latter is part of a family of
extracellular matrix glycoproteins and has previously been shown
to induce cell death by interacting with TRAIL receptors [30],
which may explain the increased cell death that we observe in
CebpaD/D HSCs.
In conclusion we have identified 397 high-confidence regions
bound by C/EBPa in LSK cells. C/EBPa binds to the proximal
promoter and distal regulatory regions of genes involved primarily
in myeloid differentiation as well as genes targeted by TFs with
roles in HSC function and lymphoid differentiation. These
findings suggest a role for C/EBPa in regulating lineage decisions
in HSCs/MPPs.
Loss of Cebpa Affects the Epigenetic Configuration of
Bivalent Genes and Pathways Involved in HSC Function
Transcriptional regulation is a complex process not only
involving TFs but also the chromatin context in which their
function is exerted. Chromatin structure and accessibility is
influenced by post-transcriptional modifications on histone tails,
which are dynamically deposited and removed by chromatin
modifying enzymes and serves as recruitment platforms for other
chromatin binding proteins [31,32]. To test if loss of Cebpa affected
chromatin structure we performed replicate ChIP-seq analysis for
the presence of two key histone marks, H3K4me3 and H3K27me3
using CebpaD/D and Cebpafl/fl LSK cells. ChIP-seq profiles of
selected genes are depicted in Figure 6 (See Figure S3A–C for
replicate data).
To systematically analyze these data, we used hierarchical
clustering to separate the epigenetic profiles into distinct clusters
and subsequently combined these with gene expression and C/
EBPa binding data (Figure 7A). From this analysis it became
evident that the vast majority of genes were highly similar in terms
of their expression and H3K4me3/H3K27me3 modification
patterns when CebpaD/D and Cebpafl/fl LSK cells were compared
(Figure 7A–C). Although some changes in histone modification
between the CebpaD/D and Cebpafl/fl genotypes reached statistical
significance, they were overall small and are therefore unlikely to
have major phenotypic consequences. One exception was the
lowly expressed cluster 6 carrying the bivalent chromatin
configuration (originally identified in ES cells [33]), which is
characterized by intermediate H3K4me3/high H3K27me3 at the
TSS and low H3K27me3 in the gene body. This cluster displayed
a specific downregulation of the H3K4me3 mark (p = 8.93610224)
around the TSS in CebpaD/D LSKs (Figure 7D, E, Table S7) and
similar to previous studies in ES cells, GO-analysis identified
pathways involved in cell differentiation, regulation of cell
differentiation and cell development to be enriched among the
group of bivalently marked genes (Figure S4, Table S8). Strikingly,
C/EBPa-bound regions were not over-represented in the bivalent
cluster and the majority of genes in this cluster did not have a C/
EBPa bound region within 100 kb of their TSS neither in the
LSKs (Table S7) nor in the GMPs (data not shown). Thus,
whereas C/EBPa is dispensable for the maintenance of the overall
H3K4me3 and H3K27me3 modification patterns, it appears to
affect the H3K4me3 status of the bivalent cluster through indirect
mechanisms. This may in turn interfere with their expression later
in differentiation, or alternatively, interfere with the ability of
CebpaD/D HSPCs to initiate differentiation.
We next took a pathway-centric approach and assessed the
epigenetic changes in a selection of the gene sets identified in the
GSEA analysis described above. Interestingly, for the stemness
signature we observed marked changes in histone modifications in
the regions flanking the TSS (Figure 8A, B). Specifically, we found
the H3K4me3 (p = 1.8361025) and H3K27me3 (p= 1.4161025)
marks to be reduced and increased, respectively, in CebpaD/D LSK
Figure 5. ChIP-seq analysis of C/EBPa binding in LSK cells. (A) Selected examples of ChIP-seq coverage of C/EBPa peaks in LSK cells. (B) ChIP-
qPCR for IgG and C/EBPa. Enrichment was determined based on a positive vs. negative primer pair. (C) The distance from all C/EBPa peaks, the 25%
highest C/EBPa peaks, or a random set, to the nearest TSS. The dashed lines represent the median. (D) Enriched TF binding motifs at C/EBPa-bound
regions. P: P-value, Af: affinity score. See also Table S3. (E) Gene set enrichment analysis of CebpaD/D HSCs compared to Cebpafl/fl HSCs for PU.1 and
EGR2 target genes. (F) GREAT analysis of C/EBPa-bound regions. See also Table S4. (G) Expression of C/EBPa targeted GO categories in CebpaD/D and
Cebpafl/fl HSCs. (H) Relative expression of C/EBPa targeted GO categories during normal myeloid differentiation. (I) Overlap of C/EBPa bound regions
in LSKs and GMPs.
doi:10.1371/journal.pgen.1004079.g005
C/EBPa Is a Key Regulator of HSC Biology
PLOS Genetics | www.plosgenetics.org 8 January 2014 | Volume 10 | Issue 1 | e1004079
cells consistent with the changes in gene expression in HSCs. The
alterations in H3K4me3 and H3K27me3 identified by ChIP-seq
were verified by qPCR on selected genes as well as genes, which
are part of the bivalent cluster and/or the stemness signature
(Figure 8C and Figure S3D). Similar to our findings for the
bivalent cluster, the majority of the genes constituting the stemness
signature did not have a C/EBPa bound region within 100 kb of
their TSS (Table S9), again suggesting that C/EBPa most likely
affects the epigenetic marks through indirect mechanisms. For the
remaining signatures we do see minor changes but none of them
reached statistical significance (Figure S5).
We hypothesized that the reduced level of H3K4me3 in
CebpaD/D LSK cells could, in part, be explained by altered levels of
H3K4me3 readers or writers. To test this we first scrutinized the
HSC gene expression data for changes in the expression of
candidate genes and noted that three probesets for Tet1 were
marginally downregulated (1.4-fold in all three probesets) in
CebpaD/D HSCs (Table S1). TET1 belongs to the TET family of
59-methylcytosine hydroxylases, which have emerged as important
epigenetic regulators of both normal and malignant hematopoiesis
[34,35,36]. TET1 has been shown to bind CpG-islands of TSSs
marked either by H3K4me3 or the bivalent H3K4me3/
H3K27me3 signature in ES cells [37,38]. To extend these data
to a hematopoietic setting we used a published TET1 dataset [37]
and found that genes bound by TET1 in ES cells were enriched in
the group of bivalently marked genes (cluster 6) in LSK cells
(Figure 8D; p,2.2610216). Moreover, when TET1 occupancy
was used to stratify the bivalent genes, the TET1 bound fraction
(56%) showed a marked decrease in H3K4me3 levels in CebpaD/D
LSKs (Figure 8E; p = 9.6610220). Interestingly, this effect was
restricted to the bivalent genes as CebpaD/D and control LSKs
showed similar H3K4me3 levels irrespectively of the binding of
TET1 (Figure 8E).
Collectively, whereas C/EBPa is largely dispensable for
H3K4me3 and H3K27me3 modification patterns in HSC/MPP,
its loss do lead to specific changes of the epigenetic states of
bivalently marked genes as well as genes associated with stem cell
function.
Discussion
Proper control of gene transcription is crucial for essentially all
biological processes and is orchestrated through a complex
interplay between TFs, chromatin structure and epigenetic
regulators. This also extends to the complex biology of HSCs as
evidenced by the fact that mice deficient for TFs or epigenetic
regulators are frequently associated with HSC phenotypes [2].
However, the mechanisms by which TFs act in a chromatin
context to regulate transcription and facilitate epigenetic changes
of HSCs are largely unknown.
In the present work we therefore analyzed the impact of
deleting C/EBPa, one of the key transcriptional regulators of
hematopoiesis, on HSC function, gene expression and the
epigenetic status of key histone modifications. We find that
conditional acute deletion of Cebpa leads to a 2-fold reduction of
immunophenotypic HSCs and that Cebpa deficient HSCs were
severely compromised. Furthermore, loss of C/EBPa promoted
their exit from quiescence and was associated with a marked
increase in cell death. These findings were supported by gene
expression analyses, which revealed prominent transcriptional
downregulation of genes associated with HSC function and
quiescence as well as upregulation of genes associated with DNA
damage and apoptosis. Among the pathways that displayed
transcriptional changes upon loss of Cebpa, we find noticeable
changes in the H3K4me3 and H3K27me3 marks flanking the
TSS for genes involved in stem cell function (stemness signature).
These genes are expressed at intermediate level (data not shown)
and their epigenetic changes may reflect a drift away from an
epigenetic state favoring self-renewal. In addition, whereas the
overall distribution of H3K4me3 and H3K27me3 marks are
largely unaltered in C/EBPa-deficient LSKs, we find that loss of
C/EBPa specifically affects the H3K4me3 status of bivalent
genes. Interestingly, TET1 was marginally downregulated in
CebpaD/D HSCs and the H3K4me3 levels were selectively reduced
in CebpaD/D LSKs at bivalent genes bound by TET1. Recently it
was suggested that TET1, together with the epigenetic regulators
CFP1 (a recruiter of the H3K4me3 methylase SETD1) and
KDM2A (a H3K36 demethylase), work synergistically to
Figure 6. ChIP-seq analysis of H3K4me3 and H3K27me3 in CebpaD/D and Cebpafl/fl HSPCs. Selected examples of H3K4me3 and H3K27me3
coverage in CebpaD/D and Cebpafl/fl HSPCs.
doi:10.1371/journal.pgen.1004079.g006
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maintain a distinct epigenetic configuration on their target genes
[39]. Thus in this context, our findings suggest that downregu-
lation of TET1 following loss of Cebpa may affect H3K4me3
status on selected genes. Whether C/EBPa affects other histone
modifications such as H3K4me1 or H3K9Ac remains to be
elucidated.
The importance of C/EBPa for HSC function has recently
been analyzed in an adult setting. Specifically, Ye et al. [23] found
that C/EBPa acts to restrict the numbers of HSCs by inhibiting
their proliferation, however the effects on HSC self-renewal was
not tested in a serial transplantation set-up. Furthermore, they
found N-Myc to be bound by C/EBPa in c-Kit+ cells and
Figure 7. Bivalent genes have lower H3K4me3 level in CebpaD/D HSPCs. (A) Clustering analysis of the H3K4me3 data at TSS and the
H3K27me3 data at TSS and gene bodies. Gene expression of CebpaD/D and Cebpafl/fl HSCs (FC = Fold change) and C/EBPa-binding within 100.000 kb
from TSS (column 1) and within 100.000 kb to nearest gene (column 2) are included. (B) Coverage density plot of the data in (A). (C) The gene
expression in HSCs (log2, arbitrary units) of clusters 1–6 was investigated. (D) The coverage sums of the clusters in (A) in 10 kb windows centered on
the TSS and across the gene body is shown. In cluster 2 and 5, the yellow, green and red curves are covered by the blue, pink and turquoise curves,
respectively. (E) P-values of the difference in H3K4me3 in TSS, H3K27me3 in TSS and GB of clusters identified in (A). Black line indicates P= 0.01.
doi:10.1371/journal.pgen.1004079.g007
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suggested that loss of C/EBPa de-repressed N-Myc and promoted
HSC expansion through an N-Myc-driven increase in proliferation.
These findings contrast those reported in the present study, where
we find C/EBPa to be important for the maintenance of a
functional HSC pool as defined by serial transplantation and
quantification of immunophenotypic HSCs. Moreover, in our
HSC gene expression analysis, we do not find N-Myc to be
upregulated, and C/EBPa does not bind the N-Myc promoter
before the GMP state (data not shown), suggesting that C/EBPa
regulates N-Myc in progenitors rather than in HSCs.
A number of methodological differences are likely to explain at
least some of the differences between the findings in our study and
those reported by Ye et al. First of all, whereas Ye et al. performed
their analyses shortly (4–7 days after the last pIpC injection), we
waited until 14–17 days after the last pIpC injection to avoid any
confounding issues with the pIpC induced interferon response.
Indeed, it has previously been reported that interferons influence
key HSC parameters such as proliferation, apoptosis and self-
renewal [40,41], and therefore, it is likely that the HSC
compartment is affected differentially 4 and 14 days after
treatment with pIpC. We therefore speculate that the effect of
C/EBPa loss on HSCs might evolve over time, from an initial
expanding phase to a strongly compromised state ultimately
resulting in increased cell death and loss of self-renewal. This
would explain the increased proliferation and expansion observed
early after deletion of Cebpa [23], the balanced HSC numbers
three weeks after deletion, the loss of HSCs in primary recipients
transplanted with C/EBPa-deficient HSCs/BM and the loss of re-
population in secondary recipients.. It is recognized that HSC
phenotypes can progress over time from proliferative to exhaustion
especially under stress such as serial transplantations as shown for
PTEN-deficiency [42,43]. Moreover, although both studies used a
conditional model that facilitates the full ablation of Cebpa, the two
models are not completely identical, which could potentially
explain some of the diverging results.
The functional consequences of Cebpa loss have also been
assessed in other developmental settings. Thus, in a pre-leukemic
setting, mutation of Cebpa leads to increased HSC proliferation but
its impact on HSC function was obscured by transformation to
AML [22] and in a fetal setting, E.14.5 LSK cells were reported to
have a competitive advantage although their proliferative status
was unaltered [21]. Together with our demonstration that loss of
Figure 8. Correlation of gene expression signatures and epigenetic alterations in CebpaD/D HSPCs. (A) Stemness genes were investigated
for histone modifications. Coverage density plot of H3K4me3 at TSS, H3K27me3 at TSS and Gene Body of stemness genes in CebpaD/D compared to
Cebpafl/fl LSK cells. Gene expression of stemness genes in CebpaD/D compared to Cebpafl/fl HSCs was included. (B) Coverage sums of the data in (A) in
10 kb windows centered on the TSS and across the gene body. (C) ChIP-qPCR for IgG, H3K4me3 and H3K27me3 on selected genes (examples from
Figure 6) and genes which are part of both the bivalent cluster 6 (Figure 7A) and the stemness signature (A). For visualization purposes the
H3K27me3 enrichment was normalized to IgG. (D) Overlap of TET1 bound regions in ES cells with bivalently marked genes in LSK cells. (E) H3K4me3
level in TSS of all or bivalent marked genes in CebpaD/D and Cebpafl/fl LSK cells.
doi:10.1371/journal.pgen.1004079.g008
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Cebpa has dramatic consequences for HSC self-renewal, these
observations suggest that different mechanisms are governing
HSC self-renewal during embryonic development, in the adult,
and in a disease context. While this concept is not novel, and is
supported by the selective importance of transcriptional regulators
such as SOX17 [7] and BMI-1 [11] in fetal versus adult HSCs, C/
EBPa is to our knowledge the first factor that impact oppositely on
fetal and adult HSCs as well as being de-regulated in disease.
Thus, our work highlights a key role of C/EBPa in HSC biology
in different developmental contexts.
TFs often operate in combinations and our data suggest that at
least some of the functional deficits of CebpaD/D HSCs may be
explained through crosstalk between C/EBPa and PU.1 - two
TFs, which have been reported to act both synergistically and
antagonistically in progenitor cells [44,45]. Our findings that ETS
binding sites are overrepresented in C/EBPa bound regions in
LSK cells and that PU.1 target genes are downregulated in
CebpaD/D HSCs suggest that C/EBPa may collaborate with PU.1
to activate a transcriptional program already in HSCs. PU.1 is
crucial for the development of almost all blood cells and even
minor alterations in its expression level have been found to impair
HSC self-renewal and lead to HSC exhaustion [46]. In this
context it is tempting to speculate that C/EBPa regulates HSC
self-renewal through crosstalk with PU.1 and that loss of C/EBPa
reduces the output of PU.1 target genes, ultimately resulting in
exhaustion of the stem cell pool.
In order to maintain hematopoietic homeostasis, HSCs have to
carefully balance the choice between a number of cell fate options.
Whereas early reports suggested that HSCs sampled different
lineage-affiliated transcriptional programs uniformly, more recent
data suggest a considerable degree of heterogeneity within the
HSC compartment [47,48,49]. Moreover, data from cell line
experiments suggest that stochastic upregulation of key regulatory
molecules including lineage-instructive TFs drives differentiation
along their respective lineages [50]. However, due to the technical
difficulties in assessing TF binding in low-abundant cell types it is
not clear whether these factors are occupying their targets already
in the HSC compartment.
When analyzing the C/EBPa bound regions in the HSC/MPP-
enriched LSK population we find these to be enriched for genes
that were upregulated during granulocytic-monocytic differentia-
tion. In addition, gene sets associated with myeloid differentiation
are downregulated in CebpaD/DHSCs, suggesting that the sampling
of myeloid transcriptional programs is in part controlled by C/
EBPa in HSCs perhaps involving PU.1 crosstalk. Hence, in
addition to its accepted role as a lineage-instructive factor required
for the transition from preGMs to GMPs [51], our data
demonstrate an additional role of C/EBPa in controlling the
sampling of myeloid gene programs already in HSCs through its
binding to the regulatory regions of myeloid genes.
Lineage choice may be viewed as a competition between distinct
lineage-affiliated programs. Interestingly, we find that loss of Cebpa
leads to upregulation of lymphoid gene expression programs in
CebpaD/D HSCs, which suggests that C/EBPa may actively repress
lymphoid differentiation perhaps through the inhibition of the
transcriptional activities of EGR family members [52,53]. This
model is also compatible with the ability of C/EBPa to
transdifferentiate lymphoid cell types into macrophages [54,55],
with the observation that a subclass of leukemia patients with
silenced C/EBPa expression develops AML associated with
distinct T-cell characteristics [56] and with the finding that pre-
leukemic Cebpa mutant GMPs readily differentiate into T-cells
[57].
In conclusion, we find that C/EBPa regulates HSC functions at
several distinct levels. Not only is its loss associated with HSC
exhaustion, but C/EBPa also appear to be involved in the
selection of the myeloid vs. lymphoid lineage suggesting that C/
EBPa primes lineage choice at the HSC level. Thus, our work
highlight the complexities by which transcriptional circuitries are
operating to maintain functional HSCs by balancing key cell fate
options such as quiescence, cell death, self-renewal and differen-
tiation.
Materials and Methods
Mouse Colony
Animals were housed according to institutional guidelines at the
University of Copenhagen and housed according to institutional
guidelines. Excision of the Cebpa allele was achieved by subjecting
10–12 weeks old Cebpafl/fl or Cebpafl/fl;Mx1Cre mice to 3 injections
(day 0, 2 and 4) with 200 ul polyinosinic-polycytidylic acid (pIpC)
(1.5 mg/ml in PBS, GE Healthcare) as described previously [58].
After conditional deletion of Cebpa, the mice were treated with
ciprofloxacin (100 mg/L, Actavis) in the drinking water. Mice
were analysed 18–21 days after first pIpC injection.
Ethics Statement
All animal work was done with approval from the Danish
Animal Ethical Committee. This study was approved by the
review board at the Faculty of Health Sciences, University of
Copenhagen.
Flow Cytometry
BM and PB was stained with antibodies and run on a LSRII
(Becton Dickinson) or FACSAria (Becton Dickinson) and analysed
using the FlowJo software. Student two-tailed T-test was used to
test for significance.
Transplantation Assays
All reconstitution assays were performed using the Ly-5
congenic mouse system. Briefly, whole BM or HSCs (LSK,
CD150+, CD482) from Ly-5.2 (CD45.2) donors were transplant-
ed by tail vein injection into 10–12 week old lethally irradiated
(900 cGy) Ly-5.1 (CD45.1) mice +/2 Ly-5.1 support BM cells.
The recipient mice were treated with ciprofloxacin (100 mg/L,
Actavis) in the drinking water. For all transplantation assays, PB
was analyzed at 3–4 weeks, 8 weeks and 16–18 weeks after
transplantation. The BM from the recipients was analyzed at the
experimental endpoint, i.e. 16–18 weeks after transplantation.
Student two-tailed T-test was used to test for significance.
Homing Assay
HSCs (LSK, CD150+, CD482) were isolated as described
above and stained with carboxyfluorescein diacetate succinimidyl
ester (CFSE) (CellTrace, Invitrogen) according to manufacturer’s
protocol. Next, HSCs (3000/mouse) were resuspended in
PBS+3% FCS and transplanted by tail vein injection into
irradiated (900 cGy) Ly-5.1 (CD45.1) mice. Twelve hours later
BM and spleen from recipients were isolated, enriched for c-Kit+
cells, and analyzed on a LSRII for CFSE+ cells. Student two-tailed
T-test was used to test for significance.
In Vitro Cell Culture
Single HSCs (LSK, CD150+, CD482) were sorted directly to
round-bottom 96-well plates and cultured in serum-free medium
(StemSpan SFEM, StemCell Technologies) supplemented with
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100 ng/ml SCF and 100 ng/ml TPO (Peprotech). Each well was
examined by microscopy and cell numbers were recorded every
other day for a week. P-values for differences in colony size were
calculated using chi-square test.
Continuous Live Imaging of HSCs
HSCs (LSK, CD150+, CD482) were sorted and cultured in
serum-free medium (StemSpan SFEM, StemCell Technologies)
supplemented with SCF (100 ng/ml), IL-3 (10 ng/ml), IL-6
(10 ng/ml), TPO (100 ng/ml) (Peprotech), EPO (5 U/ml) (Pro-
mocell), penicillin (50 U), streptomycin (50 ug/ml) and Hepes
(10 mM) (Gibco) in T12.5 flasks coated with fibronectin (Innova-
tive Research). Using cell observer (Zeiss), images were acquired
every 90 seconds using a VBA module controlling Zeiss AxioVi-
sion 4.8 software and analyzed using TTT software [59]. Student
two-tailed T-test was used to test for significance.
Gene Expression Profiling
RNA was purified from sorted HSCs (LSK, CD150+, CD482),
amplified, labeled and hybridized to the Mouse Gene 1.0 ST
GeneChip Array (Affymetrix, Santa Clara, CA, USA). Raw gene
expression data are available at the Gene Expression Omnibus
(GEO) online database under ID GSE42498.
ChIP-seq Analysis
ChIP-seq was performed using LSK or GMP cells from Cebpafl/fl
or CebpaD/D mice. Chromatin from 100.000 or 500.000 cells was
incubated with antibodies for histone marks (H3K4me3 and
H3K27me3, Cell Signaling) or C/EBPa (Santa Cruz Biotechnol-
ogy), respectively. The antibody-bound chromatin was captured
with Protein-A sepharose beads, washed, de-cross-linked and
precipitated. Precipitated DNA were mixed with 2 ng E. Coli DNA
and amplified using NEB Next ChIP-seq sample prep reagent set 1
(New England Biolabs) according to manufacturer’s protocol.
Libraries were sequenced on an Illumina Genome Analyzer IIx or
and Illumina Hiseq2000. Data was deposited in the NCBI Gene
Expression Omnibus online database under ID GSE43007. See
Table S10 for primers.
Bioinformatic Analyses
All reads were mapped using bowtie 0.12.7 [60] using standard
parameters (Figure S3B). C/EBPa peaks were called with MACS,
v. 1.4 [61] with an IgG mock sample as control and using 1*1025
as the p-value threshold. Clusters in both positional and regular
heatmaps were identified by k-means clustering using the
biopython Bio Cluster module [62]. In order to identify TF motifs
in C/EBPa bound regions, sequences below the peak summit +/
270 bp were analyzed.
Additional and detailed Materials and Methods are available as
Supporting Information (See Text S1).
Supporting Information
Figure S1 CebpaD/D mice have reduced cellularity within the BM
and altered distribution of myeloid progenitors. (A) PCR on whole
BM and spleen for wt, floxed (fl) and deleted (del) Cebpa allele from
Cebpafl/fl and CebpaD/D mice. (B) Cytospins of whole BM from
Cebpafl/fl and CebpaD/D mice. (C) BM cell number in femur and
tibia of Cebpafl/fl (n = 7) and CebpaD/D (n = 7) mice. (D) Distribution
of myeloid progenitors in Cebpafl/fl and CebpaD/D BM. (E) Mean of
(D). Cebpafl/fl (n = 6) and CebpaD/D (n = 3). Data are represented as
mean+SEM.
(EPS)
Figure S2 Gene expression analysis in Cebpafl/fl and CebpaD/D
HSCs and ChIP-seq analysis of C/EBPa binding in LSK stem and
progenitor cells. (A) Gene expression of selected genes in Cebpafl/fl
(n = 3) and CebpaD/D (n = 3) HSCs was quantified using qPCR (B)
Selected examples of ChIP-seq coverage of C/EBPa peaks in LSK
cells (replicate 2). (C) Correlation of C/EBPa ChIP-seq replicates.
(D) qPCR of selected genes in IgG and C/EBPa ChIP (replicate
2).
(EPS)
Figure S3 Analysis of replicate H3K4me3 and H3K4me27
samples. (A) Correlation of replicates in TSS +/21000 bp for
H3K4me3 and in gene bodies for H3K27me3. (B) Mapped reads
of each of the ChIP-seq samples. (C) Selected examples of ChIP-
seq coverage in LSK cells. (D) qPCR of selected genes (examples
from Figure S3C) and genes which are part of both bivalent and
stemness genes in IgG, H3K4me3 and H3K27me3 ChIP samples.
For visualization purposes the H3K27me3 enrichment was
normalized to IgG.
(EPS)
Figure S4 GO-term analysis of the bivalently marked cluster.
(EPS)
Figure S5 Analysis of H3K4me3 and H3K27me3 level in
Cebpafl/fl and CebpaD/D in signatures identified in GSEA. The
corresponding p-values were determined. The black line in the p-
value histogram indicates P= 0.01.
(TIF)
Table S1 Gene expression analysis of CebpaD/D HSCs and
Cebpafl/fl HSCs.
(XLS)
Table S2 Genes associated with C/EBPa bound regions in
LSKs. C/EBPa peaks were associated to nearest TSS. Shown are
the peak positions, the distance from the C/EBPa peaks to the
nearest gene TSS, the gene expression fold changes between
Cebpafl/fl and CebpaD/D HSCs and p-values for gene expression
changes. NA designates genes not assigned on the microarray.
(XLSX)
Table S3 Motif analysis at C/EBPa bound regions in LSKs.
Pos_hit and pos_no_hits designates the number of hits and the
number with no hits in the tested dataset, respectively. Neg_hit
and neg_no_hits designates the number of hits and the number
with no hits in the background dataset, respectively.
(XLSX)
Table S4 Pathways, GO-terms and mouse phenotypes identified
via GREAT analysis of C/EBPa bound regions in LSK cells.
(XLSX)
Table S5 Genes associated with C/EBPa bound regions in
GMPs. C/EBPa peaks were associated to nearest TSS. Shown are
the peak positions and the distance from the C/EBPa peaks to the
nearest gene TSS.
(XLSX)
Table S6 De-regulated genes in CebpaD/D HSCs and their
association with nearest C/EBPa bound region. The TSSs of
deregulated (.1.5 fold) genes were correlated to nearest C/EBPa
bound region. Shown are gene expression (log2) in HSCs, fold
change (FC), p-value and distance to nearest C/EBPa bound
region.
(XLSX)
Table S7 Distance from the TSS of genes in cluster 6 to nearest
C/EBPa bound region. Shown are normalized and scaled values
for peak coverage at the TSS (+/22000 bp) and in gene bodies
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(GB) in Cluster 6 for H3K4me3 and H3K27me3, gene expression
(log2) in HSCs, fold change (FC), p-value and distance to nearest
C/EBPa bound region.
(XLSX)
Table S8 GO-term analysis of bivalent genes in cluster 6. The
significance of enriched GO terms was assessed using hypergeo-
metric tests. In order to account for multiple testing, p-values were
corrected by Bonferroni correction.
(XLSX)
Table S9 Genes constituting the stemness signature analyzed for
gene expression in CebpaD/D and Cebpafl/fl HSCs and distance to
nearest C/EBPa bound region.
(XLSX)
Table S10 Primer sets used for qPCR.
(XLSX)
Text S1 Detailed Materials and Methods.
(DOCX)
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